- Home
- DH vs OLMA Comparison
DH vs OLMA Comparison
Compare DH & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DH
- OLMA
- Stock Information
- Founded
- DH 2011
- OLMA 2006
- Country
- DH United States
- OLMA United States
- Employees
- DH N/A
- OLMA N/A
- Industry
- DH Computer Software: Prepackaged Software
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- DH Technology
- OLMA Health Care
- Exchange
- DH Nasdaq
- OLMA Nasdaq
- Market Cap
- DH 518.7M
- OLMA 465.4M
- IPO Year
- DH 2021
- OLMA 2020
- Fundamental
- Price
- DH $4.18
- OLMA $6.10
- Analyst Decision
- DH Hold
- OLMA Strong Buy
- Analyst Count
- DH 11
- OLMA 5
- Target Price
- DH $6.15
- OLMA $26.25
- AVG Volume (30 Days)
- DH 518.0K
- OLMA 1.2M
- Earning Date
- DH 11-07-2024
- OLMA 11-12-2024
- Dividend Yield
- DH N/A
- OLMA N/A
- EPS Growth
- DH N/A
- OLMA N/A
- EPS
- DH N/A
- OLMA N/A
- Revenue
- DH $255,846,000.00
- OLMA N/A
- Revenue This Year
- DH $2.58
- OLMA N/A
- Revenue Next Year
- DH N/A
- OLMA N/A
- P/E Ratio
- DH N/A
- OLMA N/A
- Revenue Growth
- DH 3.97
- OLMA N/A
- 52 Week Low
- DH $3.19
- OLMA $5.56
- 52 Week High
- DH $10.62
- OLMA $16.78
- Technical
- Relative Strength Index (RSI)
- DH 37.96
- OLMA 27.05
- Support Level
- DH $4.05
- OLMA $5.56
- Resistance Level
- DH $4.64
- OLMA $6.87
- Average True Range (ATR)
- DH 0.20
- OLMA 0.81
- MACD
- DH -0.06
- OLMA -0.28
- Stochastic Oscillator
- DH 16.67
- OLMA 10.12
About DH Definitive Healthcare Corp.
Definitive Healthcare Corp is a provider of healthcare commercial intelligence. The company's solutions provide accurate and comprehensive information on healthcare providers and their activities to help customers optimize everything from product development to go-to-market planning and sales and marketing execution. Geographically, it derives a majority of its revenue from the United States.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.